Unverified50% confidenceFactExact time
The drugs Enveda is currently testing cover two directions: treating skin-related diseases and helping patients maintain weight loss after discontinuing GLP-1 class drugs.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
9/23/2026
First Seen
Valid until: 12/22/2026
Sources
Related Entities
Cite This Claim
Stable URI
https://kongchang.com/claim/945077API
curl https://kongchang.com/api/v1/knowledge/claims/945077MCP
get_claim(id=945077)